# OBiO Technology

Shanghai cell-and-gene-therapy CRO/CDMO (SSE STAR Market 688238) packaging plasmid, AAV, lentiviral and adenoviral vectors from research grade through GMP Phase I-III to commercial supply, alongside cell-processing and regenerative-medicine services.


Source: https://cn.bioecon.ru/companies/obio-technology/
Updated: 2026-09-18

- 国家: China
- 代码: SSE STAR: 688238

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 成立 | 2013 | https://www.obiosh.com/ |
| 总部 | 中国上海 | https://www.obiosh.com/ |
| 融资 | 于上交所科创板上市，股票代码688238 | https://q.stock.sohu.com/cn/688238/index.shtml |
| 监管批准 | 持有药品生产许可证（C证）；2026年7月宣布实现完整商业化闭环 | https://www.obiosh.com/ |
| 产能 | GMP生产覆盖I/II/III期至商业化阶段：质粒、AAV、腺病毒及其他病毒载体 | https://www.obiosh.com/ |

独立来源: q.stock.sohu.com

## 技术

- [腺病毒载体基因治疗](https://cn.bioecon.ru/technology/adenoviral-vector-gene-therapy/)